Literature DB >> 29863300

Discussing potential recurrence after lung cancer surgery: Uncertainties and challenges.

Matthew Johnson1,2, Angela Mary Tod3, Stephen Brummell2, Karen Collins2.   

Abstract

Patients with lung cancer who undergo surgery may potentially be cured. The resulting pathological staging gives an indication of 5-year survival and whether further treatment is recommended. To date, there is little research evidence regarding the way potential recurrence is communicated to patients by staff. This qualitative research used case studies to explore how information disclosure about possible recurrence was managed following lung cancer surgery and aimed to identify practice implications for clinical teams. Twelve patients were recruited and first postoperative surgical and subsequent oncology or follow-up consultations were recorded and transcribed. The perspective of the professionals involved in these clinics was ascertained through 30 in-depth interviews. Key themes in the data were identified using Framework Analysis. Recurrence risk was communicated to patients in a number of ways and levels of clarity and openness. Information provided by participants about early warning signs of recurrence varied. Findings indicate information provided was linked to the patient's prognosis and individual professionals' underlying communication approach. This study provides a unique insight into the views of lung cancer specialists regarding information disclosure and reveals the challenging nature and complexity of discussing recurrence following lung cancer surgery.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  case study research, UK; communication; information; lung cancer; recurrence risk; surgery

Mesh:

Year:  2018        PMID: 29863300     DOI: 10.1111/ecc.12870

Source DB:  PubMed          Journal:  Eur J Cancer Care (Engl)        ISSN: 0961-5423            Impact factor:   2.520


  1 in total

1.  Dominant restitution narratives of 'being lucky': An ethnographic exploration of narratives about operable lung cancer.

Authors:  Mai Nanna Schoenau
Journal:  Eur J Cancer Care (Engl)       Date:  2022-06-13       Impact factor: 2.328

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.